@article{b30e8965a640425ea7f80ff7f298caf4,
title = "Mesenchymal stem cell therapy combined with arthroscopic abrasion arthroplasty regenerates cartilage in patients with severe knee osteoarthritis: A case series",
abstract = "Aim: To evaluate the safety and efficacy of adipose-derived mesenchymal stem cell (ADMSC) therapy in combination with arthroscopic abrasion arthroplasty (AAA) in advanced knee osteoarthritis (OA). Materials & methods: 27 patients with Grade IV OA of the knee underwent AAA and ADMSC therapy (50 × 106 ADMSCs at baseline and 6 months). Clinical outcome was assessed over 36 months. Structural change was determined using MRI. Results: Treatment was well tolerated with no serious adverse events. Clinically significant improvements in pain and function were observed. Reproducible hyaline-like cartilage regeneration was seen in all participants. Conclusion: ADMSC therapy combined with AAA in Grade IV OA results in reproducible pain, functional and structural improvements. This represents a joint preservation technique for patients with advanced OA of the knee. Trial registration number: ACTRN12617000638336",
keywords = "cartilage, knee, mesenchymal stem cells, osteoarthritis, regeneration",
author = "Julien Freitag and James Wickham and Kiran Shah and Douglas Li and Cameron Norsworthy and Abi Tenen",
note = "Funding Information: J Freitag and A Tenen are clinic partners within Melbourne Stem Cell Centre. J Freitag, K Shah, D Li and A Tenen are affiliated with Magellan Stem Cells and are part of its Clinical and Scientific Advisory Committee. J Freitag is the chief clinical officer of Magellan Stem Cells. K Shah is the chief scientist at Magellan Stem Cells. The study was co-sponsored by Melbourne Stem Cell Centre and Magellan Stem Cells. Members of their Clinical and Scientific Advisory Board have been involved in the study conception and design and are listed as coauthors of this paper. Interpretation of results, and subsequent submission and publication decisions have been made independent of the sponsors. Mesenchymal stem cell therapy was performed within a private medical facility and funded by the patients/participants. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2020 Future Medicine Ltd.. All rights reserved. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = oct,
day = "21",
doi = "10.2217/rme-2020-0128",
language = "English",
volume = "15",
pages = "1957--1977",
journal = "Regenerative Medicine",
issn = "1746-0751",
publisher = "Future Medicine Ltd",
number = "8",
}